Pregnancy Rating: Category C
Lactation risk: Low concentrations of<unk>  seen in breast milk; levels are unlikely to lead to toxicity in a breast-fed infant. The manufacturer recommends that caution be used if administered to a nursing woman.
High Risk for Complications and Recommended for Treatment per CDC:
Children < 2 yo
Adults > 65 yo
Chronic Pulmonary Disease including Asthma
Cardiovascular disease (excluding hypertension only)
Renal, hepatic, hematological, and metabolic disorders (including sickle cell, diabetes)
Neurological and Neurodevelopmental disorders (brain disorders, spinal cord, peripheral nerve disorders, cerebreal palsy, epilepsy, stroke, MR, developmental delay, muscular dystrophy)
Immunosuppressed including on HAART
Pregnant or Postpartum (2 weeks after delivery)
<19 yo on long term aspirin
American Indians/Alaskan natives
Morbid Obesity (BMI >= 40)
Nursing home or chronic care facility residents.
Children < 2 yo
Adults > 65 yo
Chronic Pulmonary Disease including Asthma
Cardiovascular disease (excluding hypertension only)
Renal, hepatic, hematological, and metabolic disorders (including sickle cell, diabetes)
Neurological and Neurodevelopmental disorders (brain disorders, spinal cord, peripheral nerve disorders, cerebreal palsy, epilepsy, stroke, MR, developmental delay, muscular dystrophy)
Immunosuppressed including on HAART
Pregnant or Postpartum (2 weeks after delivery)
<19 yo on long term aspirin
American Indians/Alaskan natives
Morbid Obesity (BMI >= 40)
Nursing home or chronic care facility residents.
CrCl >31 to 60 mL/minute: 30mg BID for 5 days
CrCl >11 to 30 mL/minute: 30mg qday for 5 days
ESRD on HD CrCl≤10 mL/minute: 30mg after every hemodialysis cycle (treatment duration not to exceed 5 days)
ESRD patients on Continuous Ambulatory Peritoneal Dialysis CrCl≤10 mL/minute: Single 30mg dose administered immediately after dialysis exchange
efficacy in hepatic impairment has not been established
In general, Centers for Disease Control does not recommend seasonal or pre-exposure antiviral chemoprophylaxis, but can be considered in certain situations:
Patients at high risk of influenza complications during the first two weeks following vaccination after exposure to a person with influenza.
Patients who cannot receive influenza vaccine due to a contraindication after exposure to a person with influenza.
Prevention for people with severe immune deficiencies or others who might not respond to influenza vaccination, such as people receiving immunosuppressive medications, after exposure to a person with influenza.
To be effective as chemoprophylaxis, an antiviral medication must be taken each day for the duration of potential exposure to a person with influenza and continued for 7 days after the last known exposure. For people taking antiviral chemoprophylaxis after inactivated influenza vaccination, the recommended duration is until immunity after vaccination develops (antibody development after vaccination takes about two weeks in adults and can take longer in children depending on age and vaccination history).
Antiviral chemoprophylaxis generally is not recommended if more than 48 hours have elapsed since the first exposure to a person with influenza.
Patients at high risk of influenza complications during the first two weeks following vaccination after exposure to a person with influenza.
Patients who cannot receive influenza vaccine due to a contraindication after exposure to a person with influenza.
Prevention for people with severe immune deficiencies or others who might not respond to influenza vaccination, such as people receiving immunosuppressive medications, after exposure to a person with influenza.
Oseltamivir
Zanamivir
Peramivir
Rimantadine
Amantadine
Valganciclovir
Ribavirin
Sotrovimab